Volume 23, Number 11—November 2017
Chlamydia trachomatis Biovar L2 Infection in Women in South Africa
|Patient ID||Healthcare setting||HIV status||Co-infection||C. trachomatis WGS result||Mean read depth||Genome coverage, %|
|1||ART clinic||Positive||Trichomonas vaginalis||L2 confirmed||41||99.5|
|2||ART clinic||Positive||T. vaginalis||L2 confirmed||12||98.3|
|3||ART clinic||Positive||Mycoplasma genitalium||L2 confirmed||21||98.6|
|4||ART clinic||Positive||M.a genitalium||L2 confirmed||72||99|
|5||ART clinic||Positive||T. vaginalis||Insufficient WGS read coverage||0.5||29|
|6||STI clinic||Unknown||Neisseria gonorrhoeae||Insufficient clinical material||ND||ND|
||Insufficient clinical material
|*ART, antiretroviral therapy; ID, identification; ND, not determined; STI, sexually transmitted infection; WGS, whole-genome sequencing.|
1These authors contributed equally to this article.
Page created: October 17, 2017
Page updated: October 17, 2017
Page reviewed: October 17, 2017
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.